|Manufacturer:||Mylan Pharmaceuticals Inc.|
|Other Info:||Mylan Pharmaceuticals Inc.Morgantown, WV 26505PROB:R4AQ|
Probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis.As an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given.
-- Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
-- Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi.
-- Arthritis, especially of the great toe, as a result of gout. Acute gouty arthritis often is precipitated by trauma, infection, surgery, etc. The initial attacks are usually monoarticular but later attacks are often polyarticular.
Hypersensitivity to probenecid.Children under 2 years of age.Not recommended in persons with known blood dyscrasias or uric acid kidney stones.Therapy with probenecid should not be started until an acute gouty attack has subsided.
-- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
-- Disorders of the blood and blood forming tissues.
-- Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.
Exacerbation of gout following therapy with probenecid may occur; in such cases colchicine or other appropriate therapy is advisable.Probenecid increases plasma concentrations of methotrexate in both animals and humans.
In animal studies, increased methotrexate toxicity has been reported.
If probenecid is given with methotrexate, the dosage of methotrexate should be reduced and serum levels may need to be monitored.In patients on probenecid the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid.
The biphasic action of salicylates in the renal tubules accounts for the so-called "paradoxical effect" of uricosuric agents.
In patients on probenecid who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred.Rarely, severe allergic reactions and anaphylaxis have been reported with the use of probenecid.
Most of these have been reported to occur within several hours after readministration following prior usage of the drug.The appearance of hypersensitivity reactions requires cessation of therapy with probenecid.
This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor.
It should not to be used for self-diagnosis or treatment.